Tranexamic acid (TXA) does not create new blood clots, but it can increase the risk of clotting events by preventing your body from breaking down clots naturally. The distinction matters: this medication works by stabilizing clots that have already formed, which is exactly why it’s prescribed for heavy bleeding. But in certain people and certain situations, that same mechanism can tip the balance toward dangerous clots that would normally dissolve on their own.
How Tranexamic Acid Affects Clotting
Your body maintains a constant tug-of-war between forming clots and dissolving them. When you cut yourself, proteins rush to the site and build a clot to stop the bleeding. Once the wound heals, your body activates a cleanup system called fibrinolysis to break that clot down. Tranexamic acid works by blocking the cleanup side of this equation. It binds to a key protein involved in clot breakdown, preventing it from converting into its active form. The result is that clots stick around longer and stay more stable.
This is useful when someone is bleeding heavily, whether from surgery, trauma, or a menstrual period. But it also means that if a clot forms where it shouldn’t, such as in a deep vein in your leg or in a blood vessel supplying the lungs, your body has a harder time clearing it. Researchers have also observed that TXA may cause a small amount of additional clot formation in whole blood, though this effect is minor compared to its primary action of preserving existing clots.
What the Numbers Show
A large study examining women who took oral tranexamic acid found that the rate of venous thromboembolism (blood clots in veins, including deep vein thrombosis and pulmonary embolism) was roughly four times higher during periods of TXA use compared to non-use. The age-standardized incidence was 11.8 per 10,000 person-years among TXA users versus 2.5 per 10,000 person-years among non-users.
That fourfold increase sounds alarming, but the absolute risk remains quite low. To put it in perspective, the number needed to harm was calculated at about 78,549 women per five days of treatment. That means nearly 80,000 women would need to take a five-day course before one additional clot could be attributed to the medication. For arterial clots (the type that cause heart attacks and strokes), the difference was even smaller and not statistically significant: 3.4 per 10,000 person-years in users versus 3.0 in non-users.
So yes, the relative risk goes up meaningfully, but the baseline risk is so low that most healthy people taking short courses face very little absolute danger.
Who Should Avoid It
The risk profile changes significantly for people who already have clotting problems. Tranexamic acid is contraindicated if you have an active blood clot, including deep vein thrombosis, pulmonary embolism, or a clot in the brain. Regulatory authorities are clear on this point: if you currently have a thrombotic or embolic disorder, this medication should not be used.
Beyond active clots, prescribers are advised to assess for other risk factors before starting TXA. These include:
- Personal history of blood clots, even if resolved
- Family history of thromboembolic disease
- Other clotting risk factors such as obesity, prolonged immobility, recent surgery, smoking, or inherited clotting disorders
If any of these apply, the potential benefit of controlling bleeding needs to clearly outweigh the added clotting risk.
Combined Use With Hormonal Contraceptives
One of the most common real-world concerns involves taking tranexamic acid alongside estrogen-containing birth control, since both can independently increase clot risk. Many women prescribed TXA for heavy periods are also on the combined pill, patch, or ring. Current guidance recommends shared decision-making in this situation, meaning you and your prescriber should weigh the bleeding severity against the compounded clotting risk rather than following a blanket rule. If you’re on combined hormonal contraceptives and considering TXA, make sure your prescriber knows about both medications.
How Long the Effect Lasts
Intravenous tranexamic acid has a half-life of about two hours, meaning half the drug is cleared from your bloodstream in that time. Roughly 90% of the drug is excreted through urine within 24 hours. This relatively short duration is reassuring: once you stop taking TXA, its influence on your clotting system fades quickly. For people taking oral courses (typically a few days per menstrual cycle), the window of elevated risk is brief and resets each month.
This short clearance time also explains why the absolute clot risk remains low for most users. The drug simply isn’t in your system long enough to cause sustained clotting changes in someone without underlying risk factors.
The Bottom Line on Risk
Tranexamic acid does not initiate clot formation the way your body’s natural clotting cascade does. What it does is make it harder for your body to dissolve clots once they form. For the vast majority of healthy people taking short courses, this translates to a very small absolute increase in clot risk. For people with active clots, a history of clotting disorders, or multiple risk factors, the equation shifts, and the medication may pose genuine danger. The key variables are your personal clotting history, how long you’re taking it, and what other medications or risk factors are in the picture.